title: Inflammation-induced enhancement of the visceromotor reflex to urinary bladder distention: modulation by endogenous opioids and the effects of early-in-life experience with bladder inflammation.
abstract: Abdominal electromyographic (EMG) responses to noxious intensities of urinary bladder distention (UBD) are significantly enhanced 24 hours after zymosan-induced bladder inflammation in adult female rats. This inflammation-induced hypersensitivity is concomitantly inhibited by endogenous opioids because intraperitoneal (i.p.) naloxone administration before testing significantly increases EMG response magnitude to UBD. This inhibitory mechanism is not tonically active because naloxone does not alter EMG response magnitude to UBD in rats without inflammation. At the dose tested, naloxone does not affect bladder compliance in rats with or without inflammation. The effects of i.p. naloxone probably result from blockade of a spinal mechanism because intrathecal naloxone also significantly enhances EMG responses to UBD in rats with inflammation. Rats exposed to bladder inflammation from P90-P92 before reinflammation at P120 show similar hypersensitivity and concomitant opioid inhibition, with response magnitudes being no different from that produced by inflammation at P120 alone. In contrast, rats exposed to bladder inflammation from P14-P16 before reinflammation at P120 show markedly enhanced hypersensitivity and no evidence of concomitant opioid inhibition. These data indicate that bladder inflammation in adult rats induces bladder hypersensitivity that is inhibited by an endogenous opioidergic mechanism. This mechanism can be disrupted by neonatal bladder inflammation.
  
  
  CONCLUSIONS
  The present study observed that bladder hypersensitivity resulting from acute bladder inflammation is suppressed by an opioid-inhibitory mechanism. Experiencing bladder inflammation during the neonatal period can impair the expression of this opioid inhibitory mechanism in adulthood. This suggests that bladder insults during development may permanently alter visceral sensory systems and may represent 1 cause of painful bladder disorders.
authors: Department of Psychology, University of Alabama at Birmingham, Birmingham, Alabama 35205, USA. jenjdeb@uab.edu
authors: Jennifer
authors: J
authors: DeBerry
authors: Timothy J
authors: TJ
authors: Ness
authors: Meredith T
authors: MT
authors: Robbins
authors: Alan
authors: A
authors: Randich
mesh_terms: D000367:Age Factors; D000701:Analgesics, Opioid / Q000378:metabolism*; D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D004108:Dilatation, Pathologic; D004195:Disease Models, Animal; D004576:Electromyography / Q000379:methods; D005260:Female; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology*; D009119:Muscle Contraction / Q000502:physiology; D009270:Naloxone / Q000008:administration & dosage; D009292:Narcotic Antagonists / Q000008:administration & dosage; D010147:Pain Measurement / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D012018:Reflex / Q000187:drug effects / Q000502:physiology*; D001745:Urinary Bladder Diseases / Q000503:physiopathology*; D014781:Viscera / Q000503:physiopathology; D015054:Zymosan
chemical_list: D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D009270:Naloxone; D015054:Zymosan
references: Neurosci Lett. 1983 Aug 29;39(2):143-8
references: 6355909
references: J Auton Nerv Syst. 1983 Mar-Apr;7(3-4):339-50
references: 6192165
references: J Urol. 1985 Feb;133(2):339-42
references: 3968761
references: Brain Res. 1986 Jan;389(1-2):261-70
references: 3948011
references: Agents Actions. 1988 Dec;25(3-4):231-3
references: 3218599
references: J Physiol. 1990 Jun;425:545-62
references: 2213588
references: J Neurophysiol. 1991 Sep;66(3):1021-32
references: 1753273
references: J Neurophysiol. 1993 Feb;69(2):395-405
references: 8459274
references: Ann Med. 1995 Apr;27(2):235-9
references: 7632420
references: Brain Res. 1996 Jul 8;726(1-2):233-6
references: 8836566
references: J Neurophysiol. 1996 Nov;76(5):3025-37
references: 8930252
references: Neuroreport. 1996 Sep 2;7(13):2186-90
references: 8930986
references: Brain Res. 1996 Dec 16;743(1-2):86-92
references: 9017234
references: Brain Res. 1998 Jan 26;782(1-2):136-41
references: 9519257
references: Brain Res. 1998 Jun 8;795(1-2):197-203
references: 9622629
references: Neurosci Lett. 1998 Nov 20;257(1):9-12
references: 9857953
references: Neuroscience. 1999 Jan;88(2):499-506
references: 10197770
references: Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7719-22
references: 10393887
references: Brain Res Brain Res Rev. 2004 Nov;46(3):295-309
references: 15571771
references: J Comp Neurol. 2005 Aug 1;488(3):278-89
references: 15952166
references: BMC Urol. 2006;6:2
references: 16469099
references: Am J Physiol Regul Integr Comp Physiol. 2006 May;290(5):R1436-45
references: 16373437
references: J Pain. 2006 Jul;7(7):469-79
references: 16814686
references: Neuroreport. 2000 Jun 26;11(9):1915-9
references: 10884043
references: Science. 2000 Jul 28;289(5479):628-31
references: 10915627
references: Br J Pharmacol. 2000 Oct;131(3):610-6
references: 11015314
references: J Urol. 2001 Mar;165(3):968-74
references: 11176524
references: Neurosci Lett. 2001 Jun 22;306(1-2):97-100
references: 11403967
references: Am J Physiol Regul Integr Comp Physiol. 2002 Jan;282(1):R289-94
references: 11742850
references: Am J Physiol Gastrointest Liver Physiol. 2002 Feb;282(2):G307-16
references: 11804852
references: J Pharmacol Exp Ther. 2002 Feb;300(2):513-20
references: 11805211
references: Br J Pharmacol. 2003 Jun;139(4):741-8
references: 12812997
references: Pain. 2003 Jul;104(1-2):353-61
references: 12855345
references: Neurosci Lett. 2004 May 6;361(1-3):225-8
references: 15135934
references: Neurosci Lett. 2004 Aug 26;367(1):66-70
references: 15308299
references: Acta Pharmacol Toxicol (Copenh). 1978;43 Suppl 2:79-89
references: 362819
references: Nature. 1983 Dec 15-21;306(5944):686-8
references: 6656869